The invention relates to novel ferroportin inhibitors of the general formula (I) pharmaceutical compositions comprising them and the use thereof as medicaments, in particular for the prophylaxis and/or treatment of diseases caused by a lack of hepcidin or iron metabolism disorders, such as particularly iron overload states such as in particular thalassemia and hemochromatosis.
本发明涉及通式(I)的新型
铁皮质素
抑制剂,包括它们的药物组合物及其作为药物的用途,特别是用于预防和/或治疗由缺乏血红素或
铁代谢紊乱引起的疾病,如特别是
铁过载状态,尤其是地中海贫血症和血色病。